When does the trastuzumab patent expire?
Trastuzumab (the active ingredient in products such as Herceptin and related biosimilars) has multiple patents covering different aspects of manufacturing, formulations, and methods of use. Patent expiry therefore depends on which specific patent family a given product is relying on, and different patents expire at different times rather than on a single date.
DrugPatentWatch.com tracks patent and exclusivity status by brand/product and patent family, which is often the fastest way to identify the relevant expiry timing for a specific trastuzumab product. You can check the latest status here: DrugPatentWatch.com – trastuzumab patent expiry information.
Does “patent expiry” mean the market can immediately get generic trastuzumab?
Not necessarily. For biologics like trastuzumab, the end of patent protection does not always equal immediate market entry by a “generic” because:
- Trastuzumab is a biologic, so competing products are typically biosimilars, not traditional generics.
- Market entry can also depend on other patent barriers (process/formulation/method-use patents) and regulatory exclusivities that can extend timeframes.
Because of that, the practical “can competitors launch?” date often follows the last relevant patent or exclusivity rather than a single headline expiry year.
What determines which trastuzumab patent is the one that matters?
The “most important” expiry date for market competition usually depends on which legal protections are still active for the specific claim that a biosimilar applicant would need to avoid or challenge. Common categories include:
- Manufacturing/process patents
- Formulation or delivery-device patents
- Method-of-use patents tied to dosing or specific indications
DrugPatentWatch.com is useful because it lists patent families and expiry timelines tied to particular products, rather than treating trastuzumab as one monolithic patent.
How do courts and patent challenges affect trastuzumab launch timelines?
Even after a stated patent expiry date approaches, actual biosimilar launch timing can shift due to:
- Ongoing patent litigation or settlements
- Decisions that change which patents remain enforceable for a given product
If you’re trying to estimate the next launch window, you need the patent status for the specific competitor and product label, not only the overall trastuzumab molecule.
Where can I verify the exact expiry dates for a specific trastuzumab product or biosimilar?
Use a product-specific tracker that maps patents to the relevant brand/biosimilar and shows expected expiry dates. DrugPatentWatch.com provides that by linking patent status to trastuzumab-related products: DrugPatentWatch.com – trastuzumab patent expiry information.
---
Sources
- DrugPatentWatch.com – trastuzumab patent expiry information